OBJECTIVE: The objective of this study was to determine the effects of islet isolation and cytokine exposure on e-JUN NH2 terminal kinase (JNK) and p38 activation and whether insulin or the p38 inhibitor PD169316 could modify the response. SUMMARY BACKGROUND DATA: Islet transplantation exposes the cells of the graft to a variety of stressful stimuli that could promote beta-cell death and lead to graft failure. METHODS: Islets from canine (n = 12) and cadaveric human (n = 6) pancreata were isolated and purified. Islets were cultured in CMRL 1066 with and without 100 ng/ml insulin. The response to cytokine stimulation with tumor necrosis factor (TNF)alpha and IL-1 beta and the p38 inhibitor PD169316 was also observed. Islet lysates were analyzed by Western blotting for total and phosphorylated JNK and p38 content. Apoptosis was assessed by TdT-mediated dUTP nick end labeling (TUNEL) assay and by a specific cell death enzyme-linked immunosorbant assay (ELISA). RESULTS: In unstimulated islets, JNK activity was highest immediately following isolation, declining over 3 days to a low baseline level. The activity of p38 was lowest immediately after isolation, increasing progressively with time. The addition of insulin resulted in a more rapid decline in JNK activity, as opposed to p38, which showed no decrease in phosphorylation in response to insulin. In the cytokine stimulation studies, IL-1 beta stimulated p38 activation in a dose dependent manner, while JNK was relatively unaffected. PD169316 (100 microg/ml) was able to inhibit p38 activation in response to the isolation procedure as well as cytokine stimulation. Apoptotic activity was highest 24 hours after isolation, and was significantly reduced when islets were maintained in insulin-supplemented medium. CONCLUSIONS: Inhibition of the stress-activated protein kinase (SAPK) pathways may be important for the maintenance of islet cell survival following islet isolation for transplantation. This study supports an autocrine role of insulin in this process.
OBJECTIVE: The objective of this study was to determine the effects of islet isolation and cytokine exposure on e-JUN NH2 terminal kinase (JNK) and p38 activation and whether insulin or the p38 inhibitor PD169316 could modify the response. SUMMARY BACKGROUND DATA: Islet transplantation exposes the cells of the graft to a variety of stressful stimuli that could promote beta-cell death and lead to graft failure. METHODS: Islets from canine (n = 12) and cadaveric human (n = 6) pancreata were isolated and purified. Islets were cultured in CMRL 1066 with and without 100 ng/ml insulin. The response to cytokine stimulation with tumor necrosis factor (TNF)alpha and IL-1 beta and the p38 inhibitor PD169316 was also observed. Islet lysates were analyzed by Western blotting for total and phosphorylated JNK and p38 content. Apoptosis was assessed by TdT-mediated dUTP nick end labeling (TUNEL) assay and by a specific cell death enzyme-linked immunosorbant assay (ELISA). RESULTS: In unstimulated islets, JNK activity was highest immediately following isolation, declining over 3 days to a low baseline level. The activity of p38 was lowest immediately after isolation, increasing progressively with time. The addition of insulin resulted in a more rapid decline in JNK activity, as opposed to p38, which showed no decrease in phosphorylation in response to insulin. In the cytokine stimulation studies, IL-1 beta stimulated p38 activation in a dose dependent manner, while JNK was relatively unaffected. PD169316 (100 microg/ml) was able to inhibit p38 activation in response to the isolation procedure as well as cytokine stimulation. Apoptotic activity was highest 24 hours after isolation, and was significantly reduced when islets were maintained in insulin-supplemented medium. CONCLUSIONS: Inhibition of the stress-activated protein kinase (SAPK) pathways may be important for the maintenance of islet cell survival following islet isolation for transplantation. This study supports an autocrine role of insulin in this process.
Authors: R Alejandro; R G Cutfield; F L Shienvold; K S Polonsky; J Noel; L Olson; J Dillberger; J Miller; D H Mintz Journal: J Clin Invest Date: 1986-11 Impact factor: 14.808
Authors: D Elahi; M Nagulesparan; R J Hershcopf; D C Muller; J D Tobin; P M Blix; A H Rubenstein; R H Unger; R Andres Journal: N Engl J Med Date: 1982-05-20 Impact factor: 91.245
Authors: R Aikin; S Hanley; D Maysinger; M Lipsett; M Castellarin; S Paraskevas; L Rosenberg Journal: Diabetologia Date: 2006-10-20 Impact factor: 10.122
Authors: K Ma; C S Nunemaker; R Wu; S K Chakrabarti; D A Taylor-Fishwick; J L Nadler Journal: J Clin Endocrinol Metab Date: 2010-01-20 Impact factor: 5.958
Authors: Irina I Zaitseva; Monica Hultcrantz; Vladimir Sharoyko; Malin Flodström-Tullberg; Sergei V Zaitsev; Per-Olof Berggren Journal: Cell Mol Life Sci Date: 2009-12 Impact factor: 9.261
Authors: Yasuhiro Iwanaga; David Er Sutherland; James V Harmon; Klearchos K Papas Journal: Curr Opin Organ Transplant Date: 2008-08 Impact factor: 2.640
Authors: A Fornoni; A Pileggi; R D Molano; N Y Sanabria; T Tejada; J Gonzalez-Quintana; H Ichii; L Inverardi; C Ricordi; R L Pastori Journal: Diabetologia Date: 2007-12-08 Impact factor: 10.122
Authors: Lars G Grunnet; Reid Aikin; Morten F Tonnesen; Steven Paraskevas; Lykke Blaabjerg; Joachim Størling; Lawrence Rosenberg; Nils Billestrup; Dusica Maysinger; Thomas Mandrup-Poulsen Journal: Diabetes Date: 2009-05-26 Impact factor: 9.461